FDA Approved: YORVIPATH — Original Application (Ascendis Pharma, Endocrinology, Inc.)

View source ↗

Summary

FDA approved Yorvipath (palopegteriparatide) in an original NDA from Ascendis Pharma, Endocrinology, Inc. (NDA216490).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• YORVIPATH (palopegteriparatide)

Snippet

ORIG AP for YORVIPATH (PALOPEGTERIPARATIDE)